Gilead recorded an $820 million impairment charge in the fourth quarter of 2018 related to R&D for its KITE-585 program, which is evaluating a treatment for multiple myeloma. Gilead acquired Kite Pharma to break into the CAR-T cancer drug market to make up for waning sales of its hepatitis C drugs.
Despite the setback, Gilead ended the fourth quarter with net income of $3 million, compared to a net loss of $3.9 billion in the same period in 2017. Total revenues fell slightly to $5.8 billion in the fourth quarter of 2018, compared to $5.9 billion in the same period a year prior.
Gilead ended fiscal year 2018 with net income of $5.5 billion, up from $4.6 billion in 2017.
More articles on pharmacy:
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
Bernie Sanders takes aim at drug’s $375K price tag
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.